Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
Fierce Pharma
SEPTEMBER 17, 2024
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.
Let's personalize your content